Boyd, M. A., Amin, J., Mallon, P. W. G., Kumarasamy, N., Lombaard, J., Wood, R., Chetchotisakd, P., Phanuphak, P., Mohapi, L., Azwa, I., Belloso, W. H., Molina, J., Hoy, J., Moore, C. L., Emery, S., Cooper, D. A., & , (2017). body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet, 4(1), e13–e20. http://access.bl.uk/ark:/81055/vdc_100040771514.0x000007